Fate Therapeutics makes two appointments, one promotion
This article was originally published in Scrip
Fate Therapeutics, a biopharmaceutical company developing cellular therapeutics for the treatment of life-threatening diseases, has named Dr Wendy Levin vice-president of clinical development and Walter Grubb vice-president of business development. Dr Levin, a board-certified hematologist/oncologist, joins Fate from MEI Pharma, where she was vice-president of clinical development and medical affairs. Mr Grubb was previously executive director of business development and commercial operations at Ambit Biosciences.